To recover your password please fill in your email address
Please fill in below form to create an account with us
MOST 16 SUBSTUDY 37: PAMIPARIB
Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function
|
Trial Summary: |
The aim of this MoST-LLy substudy is to assess the clinical activity of pamiparib in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) with germline or somatic DNA repair pathway mutation (e.g. BRCA1/2), and/or BRCA mutational signature. |
|
Supported By: |
|
|
Eligibility: |
Adult patients with acute myeloid leukaemia or myelodysplastic syndrome who have no standard of care options or have failed these options and have enrolled in the MoST program and found to have germline or somatic DNA repair pathway mutation (e.g. BRCA1/2), and/or BRCA mutational signature. |
|
Registration ID: |
ACTRN12621001183875 |
|
Participation: |
National |
|
Status: |
Closed |
|
Activation Date: |
16/06/2022 |
|
Chair: |
Professor Steven Lane |
|
Contact: |